Boehringer Ingelheim Vetmedica has seen strong growth during the last calendar year, according to parent company Boehringer Ingelheim.
In a business review of 2010, it was noted that the group's animal health division experienced a 51 percent year-on-year rise in net sales, achieving total takings of 921 million euros (808.66 million pounds).
The company attributed this significant expansion in part to the acquisition of assets from Pfizer Animal Health and Fort Dodge at the end of 2009, as well as to the market success of its swine vaccine Ingelvac CircoFLEX.
It has also laid the foundations for further expansion by initiating plans to create a European research centre for animal vaccines in Hanover.
As a result, the company predicted that Boehringer Ingelheim Vetmedica will experience "further above-market growth" in the coming year.
Last month, the company was granted European approval for Ingelvac CircoFLEX to be mixed and administered simultaneously with its porcine mycoplasma vaccine, Ingelvac MycoFLEX.See all the latest jobs in Animal Health